Development-led oncology company that acquires induced-proximity programs at the stage when development decisions are most consequential
Raised to date
$250K
of $250K offered across 1 Form D filing
The company, founded in 2026 and based in New Rochelle, New York, is operating largely in stealth. It is engaging the targeted protein degradation community, including a planned presence at the 9th TPD Summit in Boston in October 2026.
A development-led model that acquires induced-proximity oncology programs at the point where development decisions are most consequential, rather than originating discovery-stage assets.
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| Apr 2, 2026 | Option to acquire | $250K/ $250K | Form D |
Therapeutics
A portfolio of acquired induced-proximity programs in oncology that the company advances through development.
Built for
Oncology drug development, with collaboration invited from biopharma partners holding induced-proximity programs
